Cardiovascular drugs are instrumental in the comprehensive management of various heart and vascular conditions. These pharmaceutical interventions are formulated to intricately modulate the cardiovascular system, addressing issues like blood pressure regulation, cholesterol reduction, and the treatment of diverse cardiovascular disorders. Among the array of cardiovascular drugs, calcium channel blockers stand out, effectively relaxing blood vessels and reducing the heart's workload. Another essential class is diuretics, which assist in flushing excess salt and water from the body, ultimately lowering blood pressure. Vasodilators, designed to widen blood vessels, are also crucial components in the pharmacological approach to cardiovascular health. The dynamic field of cardiovascular medicine continually explores innovative drug therapies to enhance patient outcomes, emphasizing the importance of tailored treatment plans and close monitoring by healthcare professionals. Patients receiving cardiovascular drugs should actively engage in their prescribed regimen, prioritize regular medical evaluations, and adopt lifestyle modifications to optimize overall cardiovascular well-being.
Title : Investigating the long-term follow up of atrial septal device closures in wales and england: A comparative analysis with major adverse cardiovascular Events (MACE)
Meera Gopinath, Cardiff University Medical school, United Kingdom
Title : An adult case of polysplenia syndrome associated with sinus node dysfunction
Apoorva Tripathi, Oxford University Hospitals, United Kingdom
Title : A unique cell-driven phenomenon in the heart and the promising future of the innovative translational tools to manage cardiac self-renewal and regeneration
Sergey Suchkov, N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Personalized and precision medicine (PPM) as a unique healthcare model through biodesign-driven translational applications and cardiology-related healthcare marketing to secure the human healthcare and biosafety
Sergey Suchkov, N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Yasser’s criterion of inferior ST-segment discrepancy deviations in AF with aberrancy and Sgarbosa criteria - a new cardiovascular discovery and management - a case report
Yasser Mohammed Hassanain Elsayed, Egyptian Ministry of Health, Egypt